Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
The first GLP-1 receptor agonist approved by the FDA, originally derived from Gila monster saliva. Available in twice-daily (Byetta) and once-weekly (Bydureon) formulations. Paved the way for semaglutide and tirzepatide.
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.
Synthetic version of exendin-4, a peptide found in Gila monster venom that shares 53% homology with human GLP-1 but resists DPP-4 degradation. Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.
Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.
- Type 2 diabetes
- Blood sugar regulation
- Modest weight loss
- Weight management
- Type 2 diabetes treatment
- Blood sugar regulation
- Cardiovascular risk reduction
- Nausea (common, especially initially)
- Pancreatitis (rare)
- Injection site nodules (Bydureon)
- Renal impairment
- Thyroid C-cell tumors (animal studies)
- Nausea and vomiting (common, usually transient)
- Pancreatitis (rare but serious)
- Gallbladder issues
- Potential thyroid tumor risk (animal studies)
- Muscle mass loss alongside fat loss
- GI side effects (diarrhea, constipation)
FDA-approved as Byetta (2005, twice daily) and Bydureon (2012, once weekly). The first-in-class GLP-1 agonist. Largely superseded by semaglutide for new prescriptions but still widely used.
FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.